Pharma’s Pipeline Getting Fuller; Parexel Finds 8.2% Jump In Trial Starts
Executive Summary
While pharmaceutical companies have been bemoaning the dearth of new drugs coming on the market, things may be looking up
You may also be interested in...
India And China Not Yet Major Sites For FDA-Regulated Trials, Parexel Finds
While India now ranks among the top 10 countries conducting FDA-regulated clinical trials, it has yet to see a major influx of trial work
Lilly Sings A New Tune: Chorus Unit Brings High Efficiency Note To Early R&D
Lilly's independently operating Chorus drug development unit has created a means to mitigate the risk of drug development by conducting small-scale, targeted experiments separate from the larger R&D organization
Pharma Maintains Steady Pace Of IND Submissions in 2005, Parexel Says
Oncologics led the pharmaceutical industry's investigational new drug application submissions over other drug classes in fiscal year 2005, according to an analysis by Parexel